Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Straynut who wrote (12382)	11/4/2019 9:54:35 AM
From: drkaz	Read Replies (1) \| Respond to of 12873

Well - at least that's finalized, and we can see what the terms were. There's that 15% royalty off the Net Sales again though. Ughhh!

To: Straynut who wrote (12382)	11/4/2019 8:18:26 PM
From: HardToFind	3 Recommendations Recommended By drkaz mattstat Savant Read Replies (2) \| Respond to of 12873

NanoViricides will not pay any upfront licensing fee under the Agreement. The Company will pay a first milestone payment to TheraCour upon the grant of approval of an Investigational New Drug application (IND), of 75,000 shares of the Company's Series A Preferred Stock. A second milestone payment will be due upon completion of Phase I human clinical trials in the cash amount of $1.5 million. A third milestone payment will be payable to TheraCour upon completion of Phase II human clinical trials in the cash amount of $2.5 million, and a fourth milestone payment will be due upon completion of Phase III human clinical trials in the cash amount of $5 million. However, NanoViricides shall have no obligation to continue clinical trials beyond Phase I. That a--hole is going to charge a total of 75,000 preferred shares, $9 million, a 15% royalty and a 30% markup on development and production expenses. The market cap of the entire NNVC company is today $8.3 million. For hell sakes, in theory he could buy back the company in totality today, and make the company pay for the purchase. How could anyone who is sober give this guy another penny to finance the company, believing there will be any return OF capital, let alone return a return ON capital? May karma be visited upon Diwan's head...

To: Straynut who wrote (12382)	11/4/2019 8:45:47 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

"We have been working diligently on completing this license agreement and have taken the time to document the licensing arrangement in a professional and deliberative process, considering the related party nature of this transaction," said Mr. Stanley Glick, Chairman of the Audit Committee, adding, "We believe that this license agreement is fair to the shareholders of NanoViricides, Inc." I call bulls--t on your statement of your belief of fairness to the shareholders. This is NOT a fair deal, nor have any to date...starting with the oldest licensing agreement we have on record, which was signed by a 70% owner of TheraCour and a 10% owner of TheraCour. Mr. Glick, may I ask two questions: Do you own any shares of NNVC? (Yahoo! Finance seems to think not.) If not, why not? Your actions speak louder than your words. You do realize you have a fudiciary responsibility to act in the shareholder's interest, right? (What a cadre of liars and thieves.)